Precision BioSciences’ (DTIL) Buy Rating Reiterated at HC Wainwright

Precision BioSciences (NASDAQ:DTIL)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $60.00 target price on the stock.

Several other brokerages have also recently issued reports on DTIL. Wall Street Zen raised Precision BioSciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. JonesTrading reiterated a “buy” rating and set a $30.00 price objective on shares of Precision BioSciences in a report on Friday, April 17th. Weiss Ratings upgraded Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $19.00 price objective on shares of Precision BioSciences in a report on Friday, March 13th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Precision BioSciences presently has an average rating of “Moderate Buy” and a consensus price target of $36.33.

Precision BioSciences Stock Up 2.5%

NASDAQ DTIL traded up $0.19 during midday trading on Wednesday, hitting $7.77. 598,250 shares of the company traded hands, compared to its average volume of 259,598. The company has a debt-to-equity ratio of 0.29, a current ratio of 14.02 and a quick ratio of 14.02. The company has a market cap of $200.48 million, a PE ratio of -2.12 and a beta of 1.31. The company’s 50-day simple moving average is $6.97 and its 200-day simple moving average is $5.39. Precision BioSciences has a 52 week low of $3.53 and a 52 week high of $8.82.

Precision BioSciences (NASDAQ:DTIL) last announced its earnings results on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.09). The company had revenue of $10.84 million for the quarter, compared to the consensus estimate of $4.05 million. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 85.37%. As a group, equities research analysts forecast that Precision BioSciences will post -1.17 earnings per share for the current year.

Institutional Trading of Precision BioSciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. HBK Sorce Advisory LLC purchased a new stake in shares of Precision BioSciences during the 4th quarter valued at $38,000. Engineers Gate Manager LP purchased a new position in Precision BioSciences in the 4th quarter worth $43,000. Occudo Quantitative Strategies LP purchased a new position in Precision BioSciences in the 4th quarter worth $52,000. Miller Financial Services LLC raised its stake in Precision BioSciences by 50.0% in the 4th quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Precision BioSciences in the 3rd quarter worth $72,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.